Resomer® RG 504, Poly(ᴅ,ʟ-lactide-co-glycolide) can be used to prepare polymeric nanoparticles that are effective carriers for anti-cancer natural substances.
Poly(D, L-lactide-co-glycolide)microspheres can be used to fabricate a hemostatic delivery device forthrombin.
Features and Benefits
Controlled release of bioactive agents, sutures and bioabsorbable implantable devices.
Legal Information
Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH
Angewandte Chemie (International ed. in English) (2019-12-17)
We report a new approach to monitor drug release from nanocarriers via a paclitaxel-methylene blue conjugate (PTX-MB) with redox activity. This construct is in a photoacoustically silent reduced state inside poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PTX-MB@PLGA NPs). During release, PTX-MB is
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging
Proceedings of the National Academy of Sciences of the United States of America, 106(14), 5497-5502 (2009-03-27)
Materials that combine facile synthesis, simple tuning of degradation rate, processability, and biocompatibility are in high demand for use in biomedical applications. We report on acetalated dextran, a biocompatible material that can be formed into microparticles with degradation rates that
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
